肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

中国淋巴瘤治疗指南(2021年版)

2021-07-03 中国抗癌协会淋巴瘤专业委员会 中华肿瘤杂志

淋巴瘤

淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6829例,死亡2807例;新发非霍奇金淋巴瘤92834例,死亡54351例。

中文标题：

中国淋巴瘤治疗指南(2021年版)

发布机构：

中国抗癌协会淋巴瘤专业委员会

发布日期：

2021-07-03

简要介绍：

淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6829例,死亡2807例;新发非霍奇金淋巴瘤92834例,死亡54351例。淋巴瘤病理类型复杂,异质性强,治疗原则各有不同。近年来,随着人们对淋巴瘤本质认识的不断深入,淋巴瘤在诊断和治疗方面出现了很多新的研究结果,患者生存得到了改善。为了及时反映国内外淋巴瘤治疗领域的进展,进一步提高中国淋巴瘤的规范化诊断和治疗水平,中国抗癌协会淋巴瘤专业委员会、中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了中国淋巴瘤治疗指南(2021年版)。

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国淋巴瘤治疗指南(2021年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=00bc91c0021ea20c, title=中国淋巴瘤治疗指南(2021年版), enTitle=, guiderFrom=中华肿瘤杂志, authorId=0, author=, summary=淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6829例,死亡2807例;新发非霍奇金淋巴瘤92834例,死亡54351例。, cover=https://img.medsci.cn/202198/1631088165713_92910.png, journalId=0, articlesId=null, associationId=1417, associationName=中国抗癌协会淋巴瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Sat Jul 03 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6829例,死亡2807例;新发非霍奇金淋巴瘤92834例,死亡54351例。淋巴瘤病理类型复杂,异质性强,治疗原则各有不同。近年来,随着人们对淋巴瘤本质认识的不断深入,淋巴瘤在诊断和治疗方面出现了很多新的研究结果,患者生存得到了改善。为了及时反映国内外淋巴瘤治疗领域的进展,进一步提高中国淋巴瘤的规范化诊断和治疗水平,中国抗癌协会淋巴瘤专业委员会、中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了中国淋巴瘤治疗指南(2021年版)。</span></p>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=412, guiderKeyword=淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6162, appHits=1159, showAppHits=0, pcHits=1946, showPcHits=5001, likes=6, shares=118, comments=49, approvalStatus=1, publishedTime=Fri Sep 03 21:37:53 CST 2021, publishedTimeString=2021-07-03, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Sep 03 16:16:42 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 10:25:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国淋巴瘤治疗指南(2021年版).pdf)])
中国淋巴瘤治疗指南(2021年版).pdf
下载请点击：
评论区 (39)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1237006, encodeId=95ce123e00675, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47345488268, createdName=guoyin0901, createdTime=Sun Aug 07 00:01:09 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209961, encodeId=3d7f1209961fa, content=感恩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sun Apr 10 07:39:53 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207109, encodeId=1512120e109d5, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ab5473666, createdName=ms3000002020390860, createdTime=Wed Mar 30 08:43:24 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202760, encodeId=6a4c1202e60e7, content=支持，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=565a5411953, createdName=ms2000000200661348, createdTime=Tue Mar 15 14:02:23 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201589, encodeId=a6d5120158930, content=非常好的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15a32475629, createdName=12448d31m45暂无昵称, createdTime=Fri Mar 11 00:06:53 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-08-07 guoyin0901

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1237006, encodeId=95ce123e00675, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47345488268, createdName=guoyin0901, createdTime=Sun Aug 07 00:01:09 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209961, encodeId=3d7f1209961fa, content=感恩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sun Apr 10 07:39:53 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207109, encodeId=1512120e109d5, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ab5473666, createdName=ms3000002020390860, createdTime=Wed Mar 30 08:43:24 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202760, encodeId=6a4c1202e60e7, content=支持，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=565a5411953, createdName=ms2000000200661348, createdTime=Tue Mar 15 14:02:23 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201589, encodeId=a6d5120158930, content=非常好的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15a32475629, createdName=12448d31m45暂无昵称, createdTime=Fri Mar 11 00:06:53 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-04-10 charly

    感恩

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1237006, encodeId=95ce123e00675, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47345488268, createdName=guoyin0901, createdTime=Sun Aug 07 00:01:09 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209961, encodeId=3d7f1209961fa, content=感恩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sun Apr 10 07:39:53 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207109, encodeId=1512120e109d5, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ab5473666, createdName=ms3000002020390860, createdTime=Wed Mar 30 08:43:24 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202760, encodeId=6a4c1202e60e7, content=支持，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=565a5411953, createdName=ms2000000200661348, createdTime=Tue Mar 15 14:02:23 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201589, encodeId=a6d5120158930, content=非常好的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15a32475629, createdName=12448d31m45暂无昵称, createdTime=Fri Mar 11 00:06:53 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-30 ms3000002020390860

    666

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1237006, encodeId=95ce123e00675, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47345488268, createdName=guoyin0901, createdTime=Sun Aug 07 00:01:09 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209961, encodeId=3d7f1209961fa, content=感恩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sun Apr 10 07:39:53 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207109, encodeId=1512120e109d5, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ab5473666, createdName=ms3000002020390860, createdTime=Wed Mar 30 08:43:24 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202760, encodeId=6a4c1202e60e7, content=支持，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=565a5411953, createdName=ms2000000200661348, createdTime=Tue Mar 15 14:02:23 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201589, encodeId=a6d5120158930, content=非常好的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15a32475629, createdName=12448d31m45暂无昵称, createdTime=Fri Mar 11 00:06:53 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-15 ms2000000200661348

    支持，学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1237006, encodeId=95ce123e00675, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47345488268, createdName=guoyin0901, createdTime=Sun Aug 07 00:01:09 CST 2022, time=2022-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209961, encodeId=3d7f1209961fa, content=感恩, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sun Apr 10 07:39:53 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207109, encodeId=1512120e109d5, content=666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6ab5473666, createdName=ms3000002020390860, createdTime=Wed Mar 30 08:43:24 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202760, encodeId=6a4c1202e60e7, content=支持，学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=565a5411953, createdName=ms2000000200661348, createdTime=Tue Mar 15 14:02:23 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201589, encodeId=a6d5120158930, content=非常好的指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=15a32475629, createdName=12448d31m45暂无昵称, createdTime=Fri Mar 11 00:06:53 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 12448d31m45暂无昵称

    非常好的指南

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020

暂未更新 · 2020-07-15

2021 共识建议：玻璃体视网膜淋巴瘤的诊断

国外肿瘤科相关专家小组（统称） · 2021-05-19

淋巴瘤 18F-FDG PET/CT及PET/MR显像临床应用指南（2021版）

中华医学会核医学分会(CSNM,Chinese Society of Nuclear Medicine) · 2021-03-28

淋巴瘤自体造血干细胞动员和采集中国专家共识（2020年版）

中华医学会血液学分会(CMA,CHINESE MEDICAL ASSOCIATION) · 2020-12-30

癌症免疫疗法协会（SITC）关于免疫疗法治疗淋巴瘤的临床实践指南2020

肿瘤免疫治疗学会(SITC,Society for Immunotherapy of Cancer) · 2020-12-16

原发性中枢神经系统淋巴瘤的MRI和PET成像共识建议：国际原发性中枢神经系统淋巴瘤协作组（IPCG）的指南声明

国际原发性中枢神经系统淋巴瘤协作组（IPCG） · 2021-02-09

拓展阅读

2010 ACR 霍奇金淋巴瘤临床I期和II期的放疗

美国放射学会(ACR,American College of Radiology) · 2010-01-01

2010 BCSH 淋巴瘤诊断报告最佳实践指南

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2010-04-01

ESMO临床诊疗指南：弥漫大B细胞非霍奇金淋巴瘤（2010）

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-21

2011 ESMO临床诊疗指南：新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 ESMO霍奇金淋巴瘤临床诊疗指南

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 中国儿童非霍奇金淋巴瘤诊疗建议

中华医学会儿科学分会血液学组 · 2011-03-01